Merck & Co., Inc. (MRK)

Merck & Co., Inc. is a global health care company operating through two reportable segments, Pharmaceutical and Animal Health, generating total sales of $64.2 billion in 2024, up from $60.1 billion in 2023 and $59.3 billion in 2022. The Pharmaceutical segment ($57.4 billion in 2024) encompasses prescription pharmaceuticals and vaccines sold primarily to wholesalers, retailers, hospitals, government agencies, and managed care organizations. Its flagship product is Keytruda, an anti-PD-1 oncology therapy generating $29.5 billion in 2024 sales and approved across numerous cancer types either as monotherapy or in combination regimens, with continued label expansions occurring through 2024 and into 2025 across the U.S., EU, Japan, and China.

Other significant pharmaceutical products include Gardasil/Gardasil 9 HPV vaccines ($8.6 billion), Januvia/Janumet diabetes treatments, Bridion, Winrevair for pulmonary arterial hypertension, Welireg for VHL disease and renal cell carcinoma, and alliance revenue from Lynparza and Lenvima shared with AstraZeneca and Eisai, respectively. The vaccine portfolio also includes ProQuad/M-M-R II/Varivax, Vaxneuvance, RotaTeq, and the newly approved Capvaxive pneumococcal vaccine. The Animal Health segment generated $5.9 billion in 2024 sales, split between Livestock ($3.5 billion) and Companion Animal ($2.4 billion) products, including parasiticides like Bravecto, vaccines such as Bovilis and Nobivac, and digital identification/traceability solutions through Allflex.

The company faces substantial competitive pressure from research-based pharmaceutical firms, generic and biosimilar manufacturers, and animal health competitors, alongside patent challenges that could affect product exclusivity. Merck also confronts significant regulatory and pricing headwinds globally, including U.S. Medicare drug price negotiations under the Inflation Reduction Act (with Januvia, Janumet, and expected future selection of Keytruda subject to government-set pricing), elimination of Medicaid rebate caps, state-level drug pricing transparency laws, EU reference pricing and new Health Technology Assessment requirements, Japan's mandated annual price reductions, and China's volume-based procurement and National Reimbursement Drug List negotiations that have driven substantial price reductions on covered products. These cost-containment measures across major markets are expected to continue negatively affecting the company's sales and profitability, prompting Merck to engage in public policy advocacy while pursuing innovation and external alliances to sustain growth.